Fact Sheet PDF

Market: Hong Kong

Stock Code: 2137.HK

ISIN: KYG1645A1094

Industry : Biotechnology

Brii Biosciences (stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.

Share Graph

Share Data

25/06/2024

Currency	HKD
Previous Close	1.07
Change (%)	1.90

Volume	828,000
Number of Shares(mil)	729.85
Share Market Cap (mil)	780.94

Pipeline

Infectious Disease Programs

Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3	NDA/BLA	Commercial	Brii Rights	Partners
Hepatitis B Treatment⁽¹⁾ Prevention	BRII-179								Global
	BRII-835 (Elebsiran) ⁽²⁾								Greater China*
	BRII-877 (Tobevibart) ⁽³⁾								Greater China*
	PreHevbri^TM⁽⁴⁾								APAC ex-Japan
HIV	BRII-732								Global	Internally discovered
HIV	BRII-753								Global	Internally discovered
MDR/XDR Gram-negative Bacterial Infections
	BRII-693								Greater China*	Monash University

NTM Lung Disease	BRII-658 (Epetraborole)⁽⁵⁾								Greater China*

Central Nervous System Disease Programs

Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3	NDA/BLA	Commercial	Brii Rights	Partners
PPD	BRII-296								Global	Internally discovered
Anxiety & Depressive Disorder	BRII-297								Global	Internally discovered

* Greater China – Mainland China, Macau, Hong Kong and Taiwan

(1) The Phase 2 combination clinical trials conducted by Brii:
• BRII-179 / PEG-IFNα
• BRII-179 / BRII-835
• BRII-835 ± PEG-IFNα
(2) Elebsiran was previously known as VIR-2218.
(3) Tobevibart was previously known as VIR-3434. The Phase 2 clinical trials have been conducted by VIR.
(4) VBI launched PreHevbrio/PreHevbri in the United States, Canada, European Union, European Economic Area, the United Kingdom, and Israel. Brii acquired exclusive rights for APAC countries (ex-Japan) in July 2023.
(5) To this date, the development and clinical trials have been conducted by AN2.

Board of Directors

	Audit and Risk Committee	Nomination Committee	Remuneration Committee	Strategic Committee	Executive Directors	Non-executive Directors	Independent Non-executive Directors
Dr. Zhi Hong
Dr. Ankang Li
Mr. Robert Taylor Nelsen
Dr. Martin J. Murphy Jr.
Ms. Grace Hui Tang
Mr. Yiu Wa Alec Tsui
Mr. Gregg Huber Alton
Dr. Taiyin Yang

Chairperson

Member

CVs of the Board Members

Corporate Executive Team

Susannah Cantrell, Ph.D.

Chief Business Officer

Eleanor (Ellee) de Groot, Ph.D.

Chief Technology Officer

Zhi Hong, Ph.D.

Executive Director
Chairman of the Board and Chief Executive Officer

Brian Alvin Johns, Ph.D.

Chief Scientific Officer

Ankang Li, Ph.D., J.D., CFA

Executive Director, Chief Strategy and Financial Officer
Chief Executive Officer of TSB Therapeutics

David Margolis, M.D., MPH

Chief Medical Officer

Karen D. Neuendorff

Chief People Officer and Head of Human Resources

Qing Zhu, Ph.D.

Head of China R&D

CVs of the Corporate Executive Team Members

Financial Highlights

BRII-B (RMB'000)	2021	2022	2023
Operating Results
Other income	99,032	107,857	163,728
Other gains and losses	45,062	(12,289)	252,402
Research and development expenses	(494,615)	(440,634)	(402,705)
Administrative expenses	(208,404)	(168,629)	(196,499)
Fair value loss on financial liabilities at FVTPL	(3,598,847)	-	-
Finance costs	(1,175)	(851)	(494)
Listing expenses	(32,137)	-	-
Loss for the year	(4,191,084)	(489,781)	(184,370)
Financial Position
Total assets	3,611,699	3,391,849	3,198,251
Total liabilities	300,443	234,352	125,869
Total equity (deficits)	3,311,256	3,157,497	3,072,382
Selected Items from Consolidated Cash Flow Statement
Net cash used in operating activities	(879,457)	(496,279)	(594,014)
Net cash used in investing activities	(475,756)	(1,433,168)	(104,350)
Net cash from financing activities	3,230,134	(3,042)	(10,977)
Net increase in cash and cash equivalents	1,874,921	(1,932,489)	(709,341)
Cash and cash equivalents at end of the year	2,855,093	1,190,572	489,650
Key indicators
Loss per share - Basic and diluted (RMB)	(9.48)	(0.67)	(0.24)
Current Ratio	1.22	1.34	2.21

Email:ir@briibio.com